Portal de Periódicos da CAPES

Cytoreductive nephrectomy in the current treatment algorithm

2019; SAGE Publishing; Volume: 11; Linguagem: Inglês

10.1177/1758835919879026

1758-8359

Teele Kuusk, Bernadett Szabados, Wing Kin Liu, Thomas Powles, Axel Bex,

Cancer Genomics and Diagnostics

The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.